Document is current
Any future updates will be listed below
-
Authors
Kurtz, David M. https://orcid.org/0000-0002-6382-4651
Soo, Joanne
Co Ting Keh, Lyron
Alig, Stefan https://orcid.org/0000-0001-6825-702X
Chabon, Jacob J. https://orcid.org/0000-0003-1820-9737
Sworder, Brian J.
Schultz, Andre https://orcid.org/0000-0002-2909-3154
Jin, Michael C.
Scherer, Florian https://orcid.org/0000-0001-9635-5487
Garofalo, Andrea
Macaulay, Charles W.
Hamilton, Emily G.
Chen, Binbin https://orcid.org/0000-0003-2973-2718
Olsen, Mari
Schroers-Martin, Joseph G. https://orcid.org/0000-0003-4128-2537
Craig, Alexander F. M.
Moding, Everett J. https://orcid.org/0000-0001-7913-5351
Esfahani, Mohammad S.
Liu, Chih Long
Dührsen, Ulrich https://orcid.org/0000-0002-4034-9472
Hüttmann, Andreas https://orcid.org/0000-0003-2230-3873
Casasnovas, René-Olivier https://orcid.org/0000-0002-1156-8983
Westin, Jason R. https://orcid.org/0000-0002-1824-2337
Roschewski, Mark https://orcid.org/0000-0003-0278-2635
Wilson, Wyndham H.
Gaidano, Gianluca https://orcid.org/0000-0002-4681-0151
Rossi, Davide
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA241076, R01CA233975, R01CA188298, R01CA233975, R01CA188298)
Damon Runyon Cancer Research Foundation (PST#09-16, DR-CI#71-14)
Conquer Cancer Foundation
American Society of Hematology
V Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 14 March 2020
Accepted: 11 June 2021
First Online: 22 July 2021
Competing interests
: D.M.K. reports paid consultancy from Roche and Genentech. A.A.A. reports research funding from Celgene and Pfizer, ownership interests in FortySeven and CiberMed, and paid consultancy from Roche, Genentech, Janssen, Pharmacyclics, Gilead, Celgene and Chugai. M.D. reports research funding from Varian Medical Systems, AstraZeneca and Illumina, ownership interest in CiberMed, and paid consultancy from Roche, AstraZeneca, Novartis, Genentech, Illumina, RefleXion, Gritstone Oncology, Boehringer Ingelheim and BioNTech. M.D., A.A.A., D.M.K., J.C. and M.S.E. report patent filings related to cancer biomarkers. M.D., A.A.A., D.M.K. and J.C. report ownership interest in Foresight Diagnostics. R.O.C. is a member of the Roche advisory board and received research support from Roche. D.R. received research support from Gilead, Janssen, Roche and AbbVie, outside the submitted work. E.J.M. has served as a paid consultant for DeciBio. The remaining authors declare no competing interests.
